<DOC>
	<DOCNO>NCT00305461</DOCNO>
	<brief_summary>The aim study compare effect ciclesonide quality life , pulmonary function time first exacerbation patient moderate persistent asthma . Ciclesonide administer daily even two dose level . The study duration consist baseline period ( 2 week ) treatment period ( 8 week ) .</brief_summary>
	<brief_title>Effect Ciclesonide Quality Life Patients With Moderate Persistent Asthma ( 21 65 ) ( BY9010/AR-101 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>Main Written inform consent Good health exception asthma Clinical diagnosis moderate persistent asthma last 6 month prior visit B0 Pretreatment inhale corticosteroid dose equivalent 250 500 mcg BDP / day stable dose last 4 week prior visit B0 , concomitant shortacting beta2agonists treatment rescue medication FEV1 ≥ 70 % ≤ 90 % predict measure least 4 h last use rescue medication visit B0 Reversibility ≥ 12 % ≥ 200 mL B0 , B0 T0 , inhalation 400 mcg salbutamol Patients compliant recommend pretreatment Main Concomitant severe disease disease contraindication use inhaled steroid Chronic obstructive pulmonary disease ( COPD ) Hospitalization within previous four week baseline Hospitalization due asthma within last twelve month Asthma exacerbation within two month previous baseline History almost fatal asthma moment Pregnancy , breast feeding , intention become pregnant course study lack safe contraception premenopausal woman Exacerbation asthma within 2 month prior entry baseline period Use systemic steroid 2 month ( injectable depot steroid 6 month ) entry baseline period , 3 time last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Ciclesonide</keyword>
</DOC>